Daewoong Pharma Ends KRW 69.23 Billion Southeast Asia Supply Deal With Abbott
Daewoong Pharma ended a supply deal with Abbott covering Southeast Asia, valued at KRW 69.23 billion.
Related stories
ABN Amro Q3 Profit Jumps, 2026 Commercial NII Forecast Raised
M impact | EQUITY | Nov 11, 2026, 06:14 AM UTC
Cathay Group Orders 14 Additional Airbus Aircraft
M impact | EQUITY | Nov 11, 2026, 06:09 AM UTC
UK projects include £1bn National Wealth Fund investment
The UK government says financing for the projects includes a £1bn investment from the UK's National Wealth Fund.
M impact | EQUITY | Nov 11, 2026, 06:07 AM UTC
RWE and KKR Announce £12 Billion Investment
The UK government says RWE and KKR have announced a total investment of £12 billion.
M impact | EQUITY | Nov 11, 2026, 06:06 AM UTC
RWE and KKR Announce £12 Billion Investment in UK
The UK government says RWE and KKR have announced a total investment of £12 billion.
M impact | EQUITY | Nov 11, 2026, 06:06 AM UTC
GoPro Delays Third-Quarter Results Over Accounting Work
GoPro said it would delay its third-quarter results, which were due Tuesday, citing previously disclosed accounting-control issues and unfinished accounting and valuation work on f
M impact | EQUITY | Nov 11, 2026, 06:04 AM UTC